Indian drug price controls confirmed

28 May 2006

A draft note for India's federal government cabinet prepared by the Ministry of Chemicals and Fertilizers, which has responsibility for thepharmaceutical sector, states that the prices of 74 drugs will continue to be frozen at their current levels under the Drug Price Control Order (DPCO) for one more year.

Additionally, as previously reported, 354 essential medicines will be brought under the DPCO for the first time (Marketletter May 15). However, the new retail controlled ceiling prices will carry an enhanced margin, that is maximum allowable post-manufacturing expense.

The draft cabinet note will be discussed and approved by federal cabinet and referred to Parliament for approval. The Chemicals and Fertiliser Ministry, according to some government officials, has proposed different kinds of cost-based control models for the 354 drugs mentioned in the National List of Essentials Medicines.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight